<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10763R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006409</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Gene Expression</subject><subject>Cell Biology/Leukocyte Signaling and Gene Expression</subject><subject>Immunology/Immune Response</subject><subject>Immunology/Immunity to Infections</subject><subject>Immunology/Immunomodulation</subject><subject>Immunology/Innate Immunity</subject><subject>Immunology/Leukocyte Activation</subject><subject>Immunology/Leukocyte Signaling and Gene Expression</subject><subject>Critical Care and Emergency Medicine/Sepsis and Multiple Organ Failure</subject><subject>Critical Care and Emergency Medicine/Trauma</subject></subj-group></article-categories><title-group><article-title>CB<sub>2</sub> Cannabinoid Receptors Contribute to Bacterial Invasion and Mortality in Polymicrobial Sepsis</article-title><alt-title alt-title-type="running-head">CB<sub>2</sub> Receptors in Sepsis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cs&#x000f3;ka</surname><given-names>Bal&#x000e1;zs</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>N&#x000e9;meth</surname><given-names>Zolt&#x000e1;n H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mukhopadhyay</surname><given-names>Partha</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spolarics</surname><given-names>Zolt&#x000e1;n</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rajesh</surname><given-names>Mohanraj</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Federici</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deitch</surname><given-names>Edwin A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>B&#x000e1;tkai</surname><given-names>S&#x000e1;ndor</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pacher</surname><given-names>P&#x000e1;l</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hask&#x000f3;</surname><given-names>Gy&#x000f6;rgy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Surgery, Morristown Memorial Hospital, Morristown, New Jersey, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Vij</surname><given-names>Neeraj</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Johns Hopkins School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>pacher@mail.nih.gov</email> (PP); <email>haskoge@umdnj.edu</email> (GH)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: BC. Performed the experiments: BC ZHN PM MR SF. Analyzed the data: BC ZS PP GH. Contributed reagents/materials/analysis tools: ED SB PP. Wrote the paper: BC PP GH.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2009</year></pub-date><volume>4</volume><issue>7</issue><elocation-id>e6409</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Sepsis is a major healthcare problem and current estimates suggest that the incidence of sepsis is approximately 750,000 annually. Sepsis is caused by an inability of the immune system to eliminate invading pathogens. It was recently proposed that endogenous mediators produced during sepsis can contribute to the immune dysfunction that is observed in sepsis. Endocannabinoids that are produced excessively in sepsis are potential factors leading to immune dysfunction, because they suppress immune cell function by binding to G-protein-coupled CB<sub>2</sub> receptors on immune cells. Here we examined the role of CB<sub>2</sub> receptors in regulating the host's response to sepsis.</p></sec><sec><title>Methods and Findings</title><p>The role of CB<sub>2</sub> receptors was studied by subjecting CB<sub>2</sub> receptor wild-type and knockout mice to bacterial sepsis induced by cecal ligation and puncture. We report that CB<sub>2</sub> receptor inactivation by knockout decreases sepsis-induced mortality, and bacterial translocation into the bloodstream of septic animals. Furthermore, CB<sub>2</sub> receptor inactivation decreases kidney and muscle injury, suppresses splenic nuclear factor (NF)-&#x003ba;B activation, and diminishes the production of IL-10, IL-6 and MIP-2. Finally, CB<sub>2</sub> receptor deficiency prevents apoptosis in lymphoid organs and augments the number of CD11b<sup>&#x0002b;</sup> and CD19<sup>&#x0002b;</sup> cells during CLP.</p></sec><sec><title>Conclusions</title><p>Taken together, our results establish for the first time that CB<sub>2</sub> receptors are important contributors to septic immune dysfunction and mortality, indicating that CB<sub>2</sub> receptors may be therapeutically targeted for the benefit of patients suffering from sepsis.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Sepsis is defined as systemic illness caused by microbial invasion of normally sterile parts of the body. Sepsis is a major healthcare problem because its incidence is in the order of sepsis is in the order of 750,000 annually, and sepsis causes more than 200,000 deaths each year in the United States alone <xref ref-type="bibr" rid="pone.0006409-Angus1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Martin1">&#x0005b;2&#x0005d;</xref>. Currently, therapeutic management of sepsis is limited mostly to supportive measures, in a large part due to a failure to fully establish the pathophysiology of this complex and heterogeneous syndrome. Multiple organ dysfunction syndrome and death in sepsis are consequences of an inability to kill invading pathogens effectively due to immunosuppression <xref ref-type="bibr" rid="pone.0006409-Benjamim1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Oberholzer1">&#x0005b;4&#x0005d;</xref>. Potentially contributing to immune suppression after a septic insult are immune cell apoptosis, inefficient phagocytosis of microbial pathogens by neutrophils and macrophages, decreased ability of antigen-presenting cells to present antigens, as well as decreased responsiveness of macrophages and T cells to release proinflammatory cytokines in conjunction with overzealous production of the anti-inflammatory cytokine IL-10 <xref ref-type="bibr" rid="pone.0006409-Hotchkiss1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Ayala1">&#x0005b;7&#x0005d;</xref>.</p><p>One view holds that immune dysfunction during sepsis is a result of autocrine/paracrine immunoregulatory mediators that are produced primarily at the site of infection/injury (including the bloodstream) and suppress immune cell function via acting on G-protein-coupled receptors. One group of these mediators are endocannabinoids, which elicit their cellular effects by binding to two subtypes of G-protein-coupled cannabinoid receptor proteins on the cell surface, termed CB<sub>1</sub> and CB<sub>2</sub> receptors <xref ref-type="bibr" rid="pone.0006409-Pacher1">&#x0005b;8&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Howlett1">&#x0005b;10&#x0005d;</xref>. Endocannabinoids are released from macrophages, dendritic cells, platelets, and parenchimal cells in response to inflammatory stimuli and oxidative stress <xref ref-type="bibr" rid="pone.0006409-DiMarzo2">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Mukhopadhyay1">&#x0005b;15&#x0005d;</xref> and are present at elevated concentrations in the sera of patients and animals suffering from septic, hemorrhagic or cardiogenic shock <xref ref-type="bibr" rid="pone.0006409-Wang1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Wagner3">&#x0005b;20&#x0005d;</xref>. CB<sub>2</sub> receptors are the dominant cannabinoid receptors on macrophages, neutrophils, and lymphocytes, and triggering CB<sub>2</sub> receptors has an overall anti-inflammatory and immunosuppressive effect <xref ref-type="bibr" rid="pone.0006409-Klein1">&#x0005b;21&#x0005d;</xref>. CB<sub>2</sub> receptor activation augments the production of the anti-inflammatory cytokine, IL-10, by murine macrophages <xref ref-type="bibr" rid="pone.0006409-Correa1">&#x0005b;22&#x0005d;</xref>, and disrupts antigen processing by these cells, which leads to incomplete antigen-presentation to T cells <xref ref-type="bibr" rid="pone.0006409-McCoy1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Matveyeva1">&#x0005b;24&#x0005d;</xref>.</p><p>Despite the recent enormous advances in our knowledge of how CB<sub>2</sub> receptors regulate immune function, the role of CB<sub>2</sub> receptors in regulating bacterial sepsis is unknown. In the present study, using a genetic approach we examined the role of CB<sub>2</sub> receptors in regulating the host's response to polymicrobial sepsis.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Experimental animals</title><p>CB<sub>2</sub> knockout (KO) mice and their wild-type (WT) littermates were developed as described previously and had been backcrossed to a C57Bl/6J background <xref ref-type="bibr" rid="pone.0006409-Batkai1">&#x0005b;14&#x0005d;</xref>. All mice were maintained in accordance with the recommendations of the &#x0201c;Guide for the Care and Use of Laboratory Animals&#x0201d;, and the experiments were approved by the New Jersey Medical School Animal Care Committee.</p></sec><sec id="s2b"><title>Cecal ligation and puncture (CLP)</title><p>Polymicrobial sepsis was induced by subjecting mice to CLP, as we have described previously <xref ref-type="bibr" rid="pone.0006409-Nemeth1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Csoka1">&#x0005b;26&#x0005d;</xref>. Eight- to twelve-week-old male CB<sub>2</sub> KO or WT mice were anesthetized with Pentobarbital (50 mg/kg), given intraperitoneally (i.p.). Under aseptic conditions, a 2-cm midline laparotomy was performed to allow exposure of the cecum with adjoining intestine. Approximately two-thirds of the cecum was tightly ligated with a 3.0 silk suture, and the ligated part of the cecum was perforated twice (through and through) with a 20-gauge needle (BD Biosciences). The cecum was then gently squeezed to extrude a small amount of feces from the perforation sites. The cecum was then returned to the peritoneal cavity and the laparotomy was closed in two layers with 4.0 silk sutures. The mice were resuscitated with 1 ml of physiological saline injected subcutaneously (s.c.) and returned to their cages with free access to food and water. One group of mice was monitored daily and survival was recorded for 7 days. Another group of mice was reanesthetized with Pentobarbital (80 mg/kg i.p.) 16 hour after the operation, and blood, peritoneal lavage fluid, and various organs were harvested.</p></sec><sec id="s2c"><title>Collection of blood, peritoneal lavage fluid, and organs</title><p>Blood samples were obtained aseptically by cardiac puncture using heparinized syringes after opening the chest and placed on ice into heparinized Eppendorf tubes until further processing for bacteriological analysis. After serial dilutions for bacteriological analysis were made (see below), the blood was centrifuged at 2,000&#x000d7;<italic>g</italic> for 10 min and the recovered plasma was stored at &#x02212;70&#x000b0;C until further use. For peritoneal lavage, the abdominal skin was cleansed with 70&#x00025; ethanol and the abdominal wall was exposed by opening the skin. Two milliliters of sterile physiological saline were then installed into the peritoneal cavity via an 18-gauge needle. The abdomen was massaged gently for 1 min while keeping the tip of the needle in the peritoneum, after which peritoneal fluid was recovered through the needle. Recovered peritoneal lavage fluid was placed on ice until processed for bacteriological examination. After serially diluting the peritoneal lavage fluid to determine colony forming unit (CFU) numbers (see below), the peritoneal lavage fluid was centrifuged at 5,000&#x000d7;<italic>g</italic> for 10 min and the supernatant was stored at &#x02212;70&#x000b0;C until further analysis. Samples from spleen and thymus, were excised and immediately frozen in liquid nitrogen.</p></sec><sec id="s2d"><title>Quantification of bacterial CFUs from peritoneal lavage fluid and blood</title><p>100 &#x000b5;l of blood or peritoneal lavage fluid was diluted serially in sterile physiological saline. 50 &#x000b5;l of each dilution was aseptically plated and cultured on trypticase blood agar plates (BD Biosciences) at 37&#x000b0;C. After 24 hours, the number of bacterial colonies was counted. Quantitative cultures are expressed as CFUs per milliliter of blood or peritoneal lavage fluid.</p></sec><sec id="s2e"><title>Flow cytometric analysis of leukocyte subsets</title><p>Flow cytometric detection of leukocyte subsets was performed as previously described <xref ref-type="bibr" rid="pone.0006409-Chandra1">&#x0005b;27&#x0005d;</xref>. In brief, the percent distribution of leukocyte subsets in blood was analyzed by specifically staining CD3<sup>&#x0002b;</sup> T-cells, CD19<sup>&#x0002b;</sup> B-cells and CD11b<sup>&#x0002b;</sup> myeloid cells using antibodies against CD markers conjugated with FITC, PERCP or PE (BD Biosciences) in three-color incubations. Aliquots of 0.1 ml whole blood were incubated with the respective markers for 15 min followed by incubation with BD FACS lysing solution (BD Biosciences) for 7 min at 37&#x000b0;C. Cells were washed twice with BD FACS wash buffer and then fixed with 1&#x00025; methanol free formaldehyde. FACS acquisitions were performed in a centralized flow cytometry facility. At least 30,000 events were collected for each analysis.</p></sec><sec id="s2f"><title>Protein extraction and Western blot analysis</title><p>Frozen organs were homogenized in a Dounce homogenizer in modified radioimmunoprecipitation assay buffer (50 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 0.25&#x00025; sodium deoxycholate, 1&#x00025; Nonidet P-40, 1 &#x000b5;g/ml pepstatin, 1 &#x000b5;g/ml leupeptin, 1 mM PMSF, 1 mM Na<sub>3</sub>VO<sub>4</sub>). The lysates were centrifuged at 15,000&#x000d7;<italic>g</italic> for 15 min, and the supernatant was recovered. Protein concentrations were determined using the Bio-Rad protein assay kit. A total of 40 &#x000b5;g of sample was separated on 8&#x02013;12&#x00025; Tris-glycine gel (Invitrogen Life Technologies) and transferred to nitrocellulose membrane. The membranes were probed with polyclonal rabbit anti-cleaved caspase-3, polyclonal rabbit anti-cleaved poly(ADP-ribose) polymerase (PARP), and polyclonal rabbit anti- inhibitory subunit of nuclear factor (NF)-&#x003ba;B (I&#x003ba;B&#x003b1;), (all from Cell Signaling Technology). Thereafter, the membranes were incubated with a secondary HRP-conjugated anti-rabbit antibody (Santa Cruz Biotechnology). HRP-conjugated polyclonal goat anti-&#x003b2; actin antibody to assess equal loading was used from Santa Cruz Biotechnology. Bands were detected using ECL Western Blotting Detection Reagent (Amersham Biosciences).</p></sec><sec id="s2g"><title>Determination of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatine phosphokinase (CK) levels</title><p>Plasma concentrations of LDH, AST, ALT, BUN, and CK were analyzed using a clinical chemistry analyzer system (VetTest8008, IDEXX Laboratories).</p></sec><sec id="s2h"><title>Determination of cytokine and chemokine levels</title><p>Concentrations of IL-10, IL-6, and MIP-2, were determined using commercially available ELISA kits (R&#x00026;D Systems) according to the manufacturer's instructions. The lower detection limit for all these cytokines was 10 pg/ml.</p></sec><sec id="s2i"><title>Statistical Analysis</title><p>Survival statistics were performed using Kaplan-Meier curve and log rank test. Two-tailed <italic>t</italic> testing was used to compare cytokine concentrations, CFUs, and other laboratory parameters. Statistical significance was assigned to <italic>p</italic> values smaller than 0.05.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>CB<sub>2</sub> receptors contribute to sepsis-induced mortality and bacterial invasion</title><p>To begin to study the role of CB<sub>2</sub> receptors, we first investigated the effect of CB<sub>2</sub> deficiency in CLP-induced septic peritonitis by monitoring the survival of CB<sub>2</sub> WT and KO mice. As demonstrated in <xref ref-type="fig" rid="pone-0006409-g001">Figure 1a</xref>, CB<sub>2</sub> receptor KO mice had significantly lower mortality rates compared with WT mice, which became apparent on the 2nd day of observation. On the 7th day following CLP, the mortality rate of CB<sub>2</sub> KO mice was markedly (by more than 40&#x00025;) lower than that of CB<sub>2</sub> WT mice. No additional changes in mortality were detected when the mice were monitored for up to 10 days (data not shown). Because persistence of local bacterial infection and bloodstream invasion play important roles in mortality in the CLP model, we next assessed the impact of CB<sub>2</sub> receptor inactivation on bacterial levels at the primary peritoneal site of infection and in the blood stream. We found markedly decreased numbers of bacteria in the blood but not peritoneal lavage fluid of CB<sub>2</sub> receptor KO mice when compared to WT animals at 16 hours after CLP (<xref ref-type="fig" rid="pone-0006409-g001">Figure 1b, c</xref>).</p><fig id="pone-0006409-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g001</object-id><label>Figure 1</label><caption><title>CB<sub>2</sub> deficiency decreases mortality and bacterial burden in polymicrobial sepsis elicited by CLP.</title><p>(a) Surviving CB<sub>2</sub> KO and WT mice were counted every day for 7 days after inducing polymicrobial sepsis by way of cecal ligation and puncture (CLP). p&#x0003c;0.001 versus WT. (b) Blood and (c) peritoneal lavage fluid obtained from CB<sub>2</sub> KO or WT mice 16 hour after CLP were cultured on soy-trypticase agar plates, and the number of bacterial colonies was counted. Data are the mean&#x000b1;SEM of <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6&#x02013;9 mice per group. &#x0002a;<italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0006409.g001"/></fig><p>Taken together, these studies document that CB<sub>2</sub> receptors contribute to bacterial translocation into the bloodstream and mortality in polymicrobial sepsis.</p></sec><sec id="s3b"><title>CB<sub>2</sub> receptor inactivation diminishes the production of IL-10, IL-6 and MIP-2 in CLP-induced sepsis</title><p>Because IL-10 overproduction contributes to the impairment of host antibacterial defenses seen in mice undergoing CLP <xref ref-type="bibr" rid="pone.0006409-Lyons1">&#x0005b;28&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Kalechman1">&#x0005b;31&#x0005d;</xref>, we next compared IL-10 in the plasma and peritoneal lavage fluid of CB<sub>2</sub> KO and WT mice subjected to CLP. CB<sub>2</sub> KO mice exhibited markedly lower levels of IL-10 at 16 h after CLP (<xref ref-type="fig" rid="pone-0006409-g002">Figure 2a, b</xref>).</p><fig id="pone-0006409-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g002</object-id><label>Figure 2</label><caption><title>CB<sub>2</sub> receptor deficiency decreases IL-10, IL-6, and MIP-2 levels in the plasma and peritoneal lavage fluid of mice subjected to CLP.</title><p>IL-10 (a,b), IL-6 (c,d) and MIP-2 (e,f) concentrations were measured at 16 hours after surgery using ELISA. Data are the mean&#x000b1;SEM of <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6&#x02013;9 mice per group. &#x0002a;&#x0002a;&#x0002a;<italic>p</italic>&#x0003c;0.001; &#x0002a;&#x0002a;<italic>p</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0006409.g002"/></fig><p>Because IL-6 blockade with neutralizing Abs has been shown to be protective in CLP-induced sepsis <xref ref-type="bibr" rid="pone.0006409-Riedemann2">&#x0005b;32&#x0005d;</xref>, we next assessed the role of CB<sub>2</sub> receptors in regulating IL-6 production during sepsis. Plasma and peritoneal lavage fluid had lower levels of IL-6 in CLP-induced CB<sub>2</sub> KO mice than their WT littermates (<xref ref-type="fig" rid="pone-0006409-g002">Figure 2c,d</xref>).</p><p>We then determined the levels of macrophage-inflammatory protein-2 (MIP-2), a crucial chemokine that mediates inflammatory responses, in the plasma and peritoneal lavage fluid of CB<sub>2</sub> KO and WT mice subjected to CLP, and we found that CLP-induced concentrations of MIP-2 were diminished in CB<sub>2</sub> KO mice as compared with their WT counterparts when measured at 16 h after CLP (<xref ref-type="fig" rid="pone-0006409-g002">Figure 2e, f</xref>).</p></sec><sec id="s3c"><title>Mice deficient in CB<sub>2</sub> receptor show decreased level of markers of tissue damage, and kidney and muscle injury</title><p>We next measured markers of disease severity and organ damage in an attempt to provide further explanation for the improved survival of CB<sub>2</sub> receptor KO mice. Levels of LDH (<xref ref-type="fig" rid="pone-0006409-g003">Figure 3a</xref>), were lower in CB<sub>2</sub> KO mice, indicating less tissue damage in general. Markers of liver (AST and ALT) function were not different between the WT and KO groups (<xref ref-type="fig" rid="pone-0006409-g003">Figure 3b, c</xref>). In addition, we could not detect any lung inflammation in CLP-challenged mice as assessed by histological analysis of lung sections, and detecting myeloperoxidase activity in lung tissue homogenates after 16 hour of CLP (data not shown). Finally, CK activity and BUN levels were lower in CB<sub>2</sub> KO mice indicating preserved kidney function and lessened muscle (both heart and skeletal) damage, respectively (<xref ref-type="fig" rid="pone-0006409-g003">Figure 3d,e</xref>).</p><fig id="pone-0006409-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g003</object-id><label>Figure 3</label><caption><title>CB<sub>2</sub> KO mice have less tissue damage, kidney and muscle injury in sepsis than their WT counterparts.</title><p>LDH (a), AST (b), ALT (c), and CK (d) activity, and BUN (e) levels were measured in plasma samples 16 hour after CLP using a clinical chemistry analyzer system (VetTest8008, IDEXX Laboratories). Data are the mean&#x000b1;SEM of <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6&#x02013;9 mice per group. &#x0002a;&#x0002a;<italic>p</italic>&#x0003c;0.01; &#x0002a; <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0006409.g003"/></fig></sec><sec id="s3d"><title>CB<sub>2</sub> receptor deficiency decreases NF-&#x003ba;B activation in CLP-induced sepsis</title><p>Microbial components and endogenous danger signals trigger the activation of signaling cascades leading to induction of the NF-&#x003ba;B system during sepsis. Persistent activation of NF-&#x003ba;B may cause excessive inflammatory responses culminating in tissue injury, organ dysfunction, and death. We, therefore, studied the activation of NF-&#x003ba;B by measuring levels of the I&#x003ba;B&#x003b1; in spleen of septic animals. As <xref ref-type="fig" rid="pone-0006409-g004">Figure 4</xref> shows, the levels of I&#x003ba;B&#x003b1; were increased in the spleen of CB<sub>2</sub> KO as compared to WT mice, indicating decreased NF-&#x003ba;B activation in KO mice.</p><fig id="pone-0006409-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g004</object-id><label>Figure 4</label><caption><title>CB<sub>2</sub> receptor deficiency is associated with augmented I&#x003ba;B&#x003b1; levels in CLP-induced sepsis.</title><p>I&#x003ba;B&#x003b1; degradation was assessed using Western blotting of spleen protein extracts of CB<sub>2</sub> WT and KO mice. Protein extracts were generated from spleen taken 16 hours after sepsis induction. Bands were detected by enchanced chemiluminescence (ECL). Results (mean&#x000b1;SEM) shown are representative of 3 experiments. &#x0002a;&#x0002a;p&#x0003c;0.01 versus WT.</p></caption><graphic xlink:href="pone.0006409.g004"/></fig></sec><sec id="s3e"><title>Genetic deletion of the CB<sub>2</sub> receptor diminishes apoptosis in lymphoid organs</title><p>Sepsis provokes extensive immune cell apoptosis that contributes to immune dysregulation and mortality. This was borne out by studies demonstrating that transfer of apoptotic splenocytes worsens survival in CLP-induced sepsis <xref ref-type="bibr" rid="pone.0006409-Hotchkiss2">&#x0005b;33&#x0005d;</xref>. Because proteolytic cleavage of caspase-3 and PARP is a good indicator of apoptosis, we tested whether CB<sub>2</sub> receptor deficiency would affect the cleavage of caspase-3 and PARP in the spleen and thymus of mice subjected to CLP. <xref ref-type="fig" rid="pone-0006409-g005">Figure 5</xref> shows that 16 hours after the onset of sepsis, the cleavage of both caspase-3 and PARP was markedly decreased in thymus and spleen of CB<sub>2</sub> receptor KO mice.</p><fig id="pone-0006409-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g005</object-id><label>Figure 5</label><caption><title>CB<sub>2</sub> receptor deficiency decreases apoptosis in septic thymus and spleen.</title><p>Proteolytic cleavage of caspase-3 and PARP in thymus and spleen protein extracts from CB<sub>2</sub> WT and KO mice was examined using Western blotting. Bands were detected by enchanced chemiluminescence (ECL). Results shown are representative of 3 experiments.</p></caption><graphic xlink:href="pone.0006409.g005"/></fig></sec><sec id="s3f"><title>Lack of CB<sub>2</sub> receptors augments the number of CD11b<sup>&#x0002b;</sup> and CD19<sup>&#x0002b;</sup> cells during CLP</title><p>CLP-challenged mice exhibit a decrease in white blood cell numbers, which includes CD11b<sup>&#x0002b;</sup> cells (mostly neutrophils), CD3<sup>&#x0002b;</sup> T lymphocytes, and CD19<sup>&#x0002b;</sup> B lymphocytes <xref ref-type="bibr" rid="pone.0006409-Hotchkiss3">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Shelley1">&#x0005b;35&#x0005d;</xref>. Unchallenged CB<sub>2</sub> KO mice have cell counts comparable to their WT counterparts <xref ref-type="bibr" rid="pone.0006409-Buckley1">&#x0005b;36&#x0005d;</xref>. Flow-cytometric analysis of cell counts revealed that CLP-challenged CB<sub>2</sub> KO mice have increased numbers of total white blood cells (<xref ref-type="fig" rid="pone-0006409-g006">Figure 6a</xref>), CD11b<sup>&#x0002b;</sup> (<xref ref-type="fig" rid="pone-0006409-g006">Figure 6b</xref>) cells and CD19<sup>&#x0002b;</sup> B lymphocytes (<xref ref-type="fig" rid="pone-0006409-g006">Figure 6c</xref>) in comparison with CB<sub>2</sub> WT mice, whereas the number of CD3<sup>&#x0002b;</sup> T cells (<xref ref-type="fig" rid="pone-0006409-g006">Figure 6d</xref>) was comparable between WT and KO mice undergoing CLP. We propose that preserved white blood cell numbers in KO animals contribute to the decreased bacterial growth and mortality of these mice.</p><fig id="pone-0006409-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006409.g006</object-id><label>Figure 6</label><caption><title>Effect of CB<sub>2</sub> receptor inactivation on the leukocyte cell subsets in the blood during CLP.</title><p>Numbers of total white cell (a), as well as CD11b<sup>&#x0002b;</sup> (b), CD19<sup>&#x0002b;</sup> (c), and CD3<sup>&#x0002b;</sup> (d) cells were monitored in blood by flow cytometric analysis after 16 hours of sepsis induced by CLP. Data are the mean&#x000b1;SEM of <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6&#x02013;9 mice per group. &#x0002a;<italic>p</italic>&#x0003c;0.05; &#x0002a;&#x0002a;<italic>p</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0006409.g006"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Current concepts suggest that sepsis is the consequence of the inability of the immune system to ward off infecting pathogens due to immune system dysfunction. The mechanisms underlying these immune functional abnormalities are largely unknown. Recent studies have expanded the list of potential mediators to molecules that are produced locally by infected and inflamed tissues and act on specific G protein-coupled receptors expressed on immune cells to inhibit their function. These molecules include adenosine <xref ref-type="bibr" rid="pone.0006409-Hasko1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Hasko2">&#x0005b;38&#x0005d;</xref>, which bind to and trigger their receptors on lymphocytes, macrophages, and neutrophils, thereby diminishing anti-bacterial defenses. In these studies we have focused on a new type of immunosuppressive G protein-coupled receptor, the CB<sub>2</sub> cannabinoid receptor, which is expressed primarily by immune cells and is activated by locally released endocannabinoids. Using the CLP model of sepsis, we found that CB<sub>2</sub> receptor activation by endogenously released cannabinoids contributes to mortality, bacterial invasion, IL-10 production, and immune cell death in sepsis.</p><p>Studies utilizing antibiotic therapy have shown that systemic bacterial dissemination is a major factor contributing to the mortality of both experimental animals and humans during sepsis <xref ref-type="bibr" rid="pone.0006409-Enoh1">&#x0005b;39&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Leibovici1">&#x0005b;41&#x0005d;</xref>. Our studies showed that bacterial burden was decreased in CB<sub>2</sub> receptor KO mice suggesting that CB<sub>2</sub> receptor activation contributes mortality by increasing systemic bacterial burden during sepsis. One potential explanation for the decreased bacterial load in mice lacking CB<sub>2</sub> receptors is a decrease in the levels of the immunosuppressive IL-10 leading to a better preserved phagocytic response. IL-10 is an immunoregulatory cytokine that is released primarily by macrophages during sepsis. IL-10 is an important contributor to the dysregulated immune system that is observed in sepsis <xref ref-type="bibr" rid="pone.0006409-Lyons1">&#x0005b;28&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Kalechman1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Oberholzer2">&#x0005b;42&#x0005d;</xref>. Recent studies have shown that CB<sub>2</sub> receptor activation can upregulate IL-10 production across a number of experimental systems that utilize macrophages <xref ref-type="bibr" rid="pone.0006409-Correa1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006409-Zhu1">&#x0005b;43&#x0005d;</xref>. Given the relevance of IL-10 in sepsis, the effect of CB<sub>2</sub> receptor activation on IL-10 release is likely to be a major determinant of the immunomodulatory action of CB<sub>2</sub> receptor activation in sepsis.</p><p>Sepsis instigates widespread immune cell apoptosis, and mortality in this illness is thought to be, at least in part, a consequence of dysregulated immune cell death <xref ref-type="bibr" rid="pone.0006409-Chung1">&#x0005b;44&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Hotchkiss5">&#x0005b;46&#x0005d;</xref>. CB<sub>2</sub> receptor triggering induces both T and B lymphocyte apoptosis in vitro <xref ref-type="bibr" rid="pone.0006409-Lombard1">&#x0005b;47&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006409-Do1">&#x0005b;52&#x0005d;</xref>. Our data showing decreased levels of caspase-3 cleavage as well as PARP cleavage in CB<sub>2</sub> KO mice following sepsis indicate that CB<sub>2</sub> receptors are essential contributors to apoptotic processes also in vivo. Moreover, we found increased numbers of CD11b<sup>&#x0002b;</sup> and CD19<sup>&#x0002b;</sup>cells in blood of CB<sub>2</sub> KO mice suggesting that CB<sub>2</sub> receptors contribute to bacterial invasion by CD11b<sup>&#x0002b;</sup> and B cell depletion in the bloodstream. The immunosuppressive role of CB<sub>2</sub> receptors has been confirmed recently in vivo by inducing immune-mediated inflammatory disease in CB<sub>2</sub> receptor KO and WT mice. CB<sub>2</sub> receptor KO mice develop a more severe form of experimental allergic encephalomyelitis in comparison with WT mice, which is a consequence of increased T-cell activation and decreased T-cell apoptosis in KO vs. WT mice <xref ref-type="bibr" rid="pone.0006409-Maresz1">&#x0005b;53&#x0005d;</xref>. In another model, CB<sub>2</sub> receptor KO mice displayed increased allergic responses in the skin, which was secondary to increased production of proinflammatory cytokines <xref ref-type="bibr" rid="pone.0006409-Karsak1">&#x0005b;54&#x0005d;</xref>. Moreover, we have recently demonstrated that CB<sub>2</sub> receptor KO mice exhibit exacerbated liver injury following hepatic ischemia/reperfusion, which is associated with increased production of pro-inflammatory cytokines and neutrophil infiltration into the liver <xref ref-type="bibr" rid="pone.0006409-Batkai1">&#x0005b;14&#x0005d;</xref>. Our results that CB<sub>2</sub> receptor inactivation decreases mortality during CLP-induced bacterial (non-sterile) sepsis might seem contradictory to the observations in experimental allergic encephalomyelitis, allergic skin inflammation, and ischemia/reperfusion-induced inflammation in that CB<sub>2</sub> receptor inactivation is injurious in these sterile inflammation models. But we believe the data seen as a whole suggests that differences in outcome in the two types of model are due to immunosuppression being beneficial in sterile inflammation/ischemia but detrimental in clinically relevant models of infection-induced sepsis where mortality depends more upon the inability to mount an immune response leading to a loss of control of bacterial growth.</p><p>In summary, we found that CB<sub>2</sub> receptor activation by endogenously released cannabinoids contributes to mortality, bacterial invasion, IL-10 production, and immune cell death in sepsis. Based on these observations, we suggest that CB<sub>2</sub> receptor triggering contributes to the development of immune system dysfunction that leads to mortality in sepsis.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0006409-Angus1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Linde-Zwirble</surname><given-names>WT</given-names></name><name><surname>Lidicker</surname><given-names>J</given-names></name><name><surname>Clermont</surname><given-names>G</given-names></name><name><surname>Carcillo</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Epidemiology of severe sepsis in the united states: Analysis of incidence, outcome, and associated costs of care.</article-title><source>Crit Care Med</source><volume>29(7)</volume><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">11445675</pub-id></mixed-citation></ref><ref id="pone.0006409-Martin1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>GS</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>The epidemiology of sepsis in the united states from 1979 through 2000.</article-title><source>N Engl J Med</source><volume>348(16)</volume><fpage>1546</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">12700374</pub-id></mixed-citation></ref><ref id="pone.0006409-Benjamim1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamim</surname><given-names>CF</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name></person-group><year>2004</year><article-title>The chronic consequences of severe sepsis.</article-title><source>J Leukoc Biol</source><volume>75(3)</volume><fpage>408</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">14557384</pub-id></mixed-citation></ref><ref id="pone.0006409-Oberholzer1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberholzer</surname><given-names>A</given-names></name><name><surname>Oberholzer</surname><given-names>C</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name></person-group><year>2001</year><article-title>Sepsis syndromes: Understanding the role of innate and acquired immunity.</article-title><source>Shock</source><volume>16(2)</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11508871</pub-id></mixed-citation></ref><ref id="pone.0006409-Hotchkiss1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Karl</surname><given-names>IE</given-names></name></person-group><year>2003</year><article-title>The pathophysiology and treatment of sepsis.</article-title><source>N Engl J Med</source><volume>348(2)</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">12519925</pub-id></mixed-citation></ref><ref id="pone.0006409-Riedemann1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedemann</surname><given-names>NC</given-names></name><name><surname>Guo</surname><given-names>RF</given-names></name><name><surname>Bernacki</surname><given-names>KD</given-names></name><name><surname>Reuben</surname><given-names>JS</given-names></name><name><surname>Laudes</surname><given-names>IJ</given-names></name><etal/></person-group><year>2003</year><article-title>Regulation by C5a of neutrophil activation during sepsis.</article-title><source>Immunity</source><volume>19(2)</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12932353</pub-id></mixed-citation></ref><ref id="pone.0006409-Ayala1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name></person-group><year>1996</year><article-title>Immune dysfunction in murine polymicrobial sepsis: Mediators, macrophages, lymphocytes and apoptosis.</article-title><source>Shock</source><volume>6</volume><issue>Suppl 1</issue><fpage>S27</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">8828095</pub-id></mixed-citation></ref><ref id="pone.0006409-Pacher1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>The endocannabinoid system as an emerging target of pharmacotherapy.</article-title><source>Pharmacol Rev</source><volume>58(3)</volume><fpage>389</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">16968947</pub-id></mixed-citation></ref><ref id="pone.0006409-DiMarzo1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name></person-group><year>2008</year><article-title>Targeting the endocannabinoid system: To enhance or reduce?</article-title><source>Nat Rev Drug Discov</source><volume>7(5)</volume><fpage>438</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">18446159</pub-id></mixed-citation></ref><ref id="pone.0006409-Howlett1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>AC</given-names></name><name><surname>Barth</surname><given-names>F</given-names></name><name><surname>Bonner</surname><given-names>TI</given-names></name><name><surname>Cabral</surname><given-names>G</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name><etal/></person-group><year>2002</year><article-title>International union of pharmacology. XXVII. classification of cannabinoid receptors.</article-title><source>Pharmacol Rev</source><volume>54(2)</volume><fpage>161</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12037135</pub-id></mixed-citation></ref><ref id="pone.0006409-DiMarzo2"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>De Petrocellis</surname><given-names>L</given-names></name><name><surname>Sepe</surname><given-names>N</given-names></name><name><surname>Buono</surname><given-names>A</given-names></name></person-group><year>1996</year><article-title>Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells.</article-title><source>Biochem J</source><volume>316 ( Pt 3)(Pt 3)</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">8670178</pub-id></mixed-citation></ref><ref id="pone.0006409-Pacher2"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Hasko</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.</article-title><source>Br J Pharmacol</source><volume>153(2)</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">18026124</pub-id></mixed-citation></ref><ref id="pone.0006409-Matias1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matias</surname><given-names>I</given-names></name><name><surname>Pochard</surname><given-names>P</given-names></name><name><surname>Orlando</surname><given-names>P</given-names></name><name><surname>Salzet</surname><given-names>M</given-names></name><name><surname>Pestel</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Presence and regulation of the endocannabinoid system in human dendritic cells.</article-title><source>Eur J Biochem</source><volume>269(15)</volume><fpage>3771</fpage><lpage>3778</lpage><pub-id pub-id-type="pmid">12153574</pub-id></mixed-citation></ref><ref id="pone.0006409-Batkai1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Osei-Hyiaman</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>El-Assal</surname><given-names>O</given-names></name><name><surname>Rajesh</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury.</article-title><source>FASEB J</source><volume>21(8)</volume><fpage>1788</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">17327359</pub-id></mixed-citation></ref><ref id="pone.0006409-Mukhopadhyay1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>P</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Rajesh</surname><given-names>M</given-names></name><name><surname>Czifra</surname><given-names>N</given-names></name><name><surname>Harvey-White</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.</article-title><source>J Am Coll Cardiol</source><volume>50(6)</volume><fpage>528</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">17678736</pub-id></mixed-citation></ref><ref id="pone.0006409-Wang1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Hashiguchi</surname><given-names>T</given-names></name><name><surname>Kitajima</surname><given-names>I</given-names></name><etal/></person-group><year>2001</year><article-title>Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: Increase in endogenous cannabinoids in the sera of patients with endotoxic shock.</article-title><source>Anal Biochem</source><volume>294(1)</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11412008</pub-id></mixed-citation></ref><ref id="pone.0006409-Varga1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Bridgen</surname><given-names>DT</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><year>1998</year><article-title>Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension.</article-title><source>FASEB J</source><volume>12(11)</volume><fpage>1035</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">9707176</pub-id></mixed-citation></ref><ref id="pone.0006409-Wagner1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Varga</surname><given-names>K</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><year>1998</year><article-title>Cardiovascular actions of cannabinoids and their generation during shock.</article-title><source>J Mol Med</source><volume>76(12)</volume><fpage>824</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">9846953</pub-id></mixed-citation></ref><ref id="pone.0006409-Wagner2"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Varga</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>EF</given-names></name><name><surname>Rzigalinski</surname><given-names>BA</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><etal/></person-group><year>1997</year><article-title>Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.</article-title><source>Nature</source><volume>390(6659)</volume><fpage>518</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">9394002</pub-id></mixed-citation></ref><ref id="pone.0006409-Wagner3"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Bauersachs</surname><given-names>J</given-names></name><name><surname>Karcher</surname><given-names>J</given-names></name><name><surname>Wiesler</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.</article-title><source>J Am Coll Cardiol</source><volume>38(7)</volume><fpage>2048</fpage><lpage>2054</lpage><pub-id pub-id-type="pmid">11738314</pub-id></mixed-citation></ref><ref id="pone.0006409-Klein1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>TW</given-names></name></person-group><year>2005</year><article-title>Cannabinoid-based drugs as anti-inflammatory therapeutics.</article-title><source>Nat Rev Immunol</source><volume>5(5)</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">15864274</pub-id></mixed-citation></ref><ref id="pone.0006409-Correa1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>F</given-names></name><name><surname>Mestre</surname><given-names>L</given-names></name><name><surname>Docagne</surname><given-names>F</given-names></name><name><surname>Guaza</surname><given-names>C</given-names></name></person-group><year>2005</year><article-title>Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: Role of IL-10 and ERK1/2 kinase signaling.</article-title><source>Br J Pharmacol</source><volume>145(4)</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">15821753</pub-id></mixed-citation></ref><ref id="pone.0006409-McCoy1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>KL</given-names></name><name><surname>Matveyeva</surname><given-names>M</given-names></name><name><surname>Carlisle</surname><given-names>SJ</given-names></name><name><surname>Cabral</surname><given-names>GA</given-names></name></person-group><year>1999</year><article-title>Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation.</article-title><source>J Pharmacol Exp Ther</source><volume>289(3)</volume><fpage>1620</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">10336560</pub-id></mixed-citation></ref><ref id="pone.0006409-Matveyeva1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matveyeva</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>CB</given-names></name><name><surname>Harrison</surname><given-names>MT</given-names></name><name><surname>Cabral</surname><given-names>GA</given-names></name><name><surname>McCoy</surname><given-names>KL</given-names></name></person-group><year>2000</year><article-title>Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages.</article-title><source>Int J Immunopharmacol</source><volume>22(5)</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">10708885</pub-id></mixed-citation></ref><ref id="pone.0006409-Nemeth1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>ZH</given-names></name><name><surname>Csoka</surname><given-names>B</given-names></name><name><surname>Wilmanski</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><etal/></person-group><year>2006</year><article-title>Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis.</article-title><source>J Immunol</source><volume>176(9)</volume><fpage>5616</fpage><lpage>5626</lpage><pub-id pub-id-type="pmid">16622031</pub-id></mixed-citation></ref><ref id="pone.0006409-Csoka1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csoka</surname><given-names>B</given-names></name><name><surname>Nemeth</surname><given-names>ZH</given-names></name><name><surname>Selmeczy</surname><given-names>Z</given-names></name><name><surname>Koscso</surname><given-names>B</given-names></name><name><surname>Pacher</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Role of A(2A) adenosine receptors in regulation of opsonized E. coli-induced macrophage function.</article-title><source>Purinergic Signal</source><volume>3(4)</volume><fpage>447</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">18404457</pub-id></mixed-citation></ref><ref id="pone.0006409-Chandra1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>R</given-names></name><name><surname>Villanueva</surname><given-names>E</given-names></name><name><surname>Feketova</surname><given-names>E</given-names></name><name><surname>Machiedo</surname><given-names>GW</given-names></name><name><surname>Hasko</surname><given-names>G</given-names></name><etal/></person-group><year>2008</year><article-title>Endotoxemia down-regulates bone marrow lymphopoiesis but stimulates myelopoiesis: The effect of G6PD deficiency.</article-title><source>J Leukoc Biol</source><volume>83(6)</volume><fpage>1541</fpage><lpage>1550</lpage><pub-id pub-id-type="pmid">18353927</pub-id></mixed-citation></ref><ref id="pone.0006409-Lyons1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>JL</given-names></name><name><surname>Rodrick</surname><given-names>ML</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name></person-group><year>1997</year><article-title>Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection.</article-title><source>Ann Surg</source><volume>226(4)</volume><fpage>450</fpage><lpage>8; discussion 458&#x02013;60</lpage><pub-id pub-id-type="pmid">9351713</pub-id></mixed-citation></ref><ref id="pone.0006409-Steinhauser1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhauser</surname><given-names>ML</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Lukacs</surname><given-names>NW</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name><etal/></person-group><year>1999</year><article-title>IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.</article-title><source>J Immunol</source><volume>162(1)</volume><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">9886412</pub-id></mixed-citation></ref><ref id="pone.0006409-Song1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>GY</given-names></name><name><surname>Chung</surname><given-names>CS</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>Immune suppression in polymicrobial sepsis: Differential regulation of Th1 and Th2 responses by p38 MAPK.</article-title><source>J Surg Res</source><volume>91(2)</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">10839963</pub-id></mixed-citation></ref><ref id="pone.0006409-Kalechman1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalechman</surname><given-names>Y</given-names></name><name><surname>Gafter</surname><given-names>U</given-names></name><name><surname>Gal</surname><given-names>R</given-names></name><name><surname>Rushkin</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><etal/></person-group><year>2002</year><article-title>Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: Dependence on timing of immunomodulating intervention.</article-title><source>J Immunol</source><volume>169(1)</volume><fpage>384</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">12077268</pub-id></mixed-citation></ref><ref id="pone.0006409-Riedemann2"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedemann</surname><given-names>NC</given-names></name><name><surname>Neff</surname><given-names>TA</given-names></name><name><surname>Guo</surname><given-names>RF</given-names></name><name><surname>Bernacki</surname><given-names>KD</given-names></name><name><surname>Laudes</surname><given-names>IJ</given-names></name><etal/></person-group><year>2003</year><article-title>Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.</article-title><source>J Immunol</source><volume>170(1)</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">12496437</pub-id></mixed-citation></ref><ref id="pone.0006409-Hotchkiss2"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Grayson</surname><given-names>MH</given-names></name><name><surname>Tinsley</surname><given-names>KW</given-names></name><name><surname>Dunne</surname><given-names>BS</given-names></name><etal/></person-group><year>2003</year><article-title>Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100(11)</volume><fpage>6724</fpage><lpage>6729</lpage><pub-id pub-id-type="pmid">12736377</pub-id></mixed-citation></ref><ref id="pone.0006409-Hotchkiss3"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Cobb</surname><given-names>JP</given-names></name><name><surname>Jacobson</surname><given-names>A</given-names></name><name><surname>Buchman</surname><given-names>TG</given-names></name><etal/></person-group><year>1997</year><article-title>Apoptosis in lymphoid and parenchymal cells during sepsis: Findings in normal and T- and B-cell-deficient mice.</article-title><source>Crit Care Med</source><volume>25(8)</volume><fpage>1298</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">9267941</pub-id></mixed-citation></ref><ref id="pone.0006409-Shelley1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelley</surname><given-names>O</given-names></name><name><surname>Murphy</surname><given-names>T</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name></person-group><year>2003</year><article-title>Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury.</article-title><source>Shock</source><volume>20(2)</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">12865655</pub-id></mixed-citation></ref><ref id="pone.0006409-Buckley1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>NE</given-names></name><name><surname>McCoy</surname><given-names>KL</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Bonner</surname><given-names>T</given-names></name><name><surname>Zimmer</surname><given-names>A</given-names></name><etal/></person-group><year>2000</year><article-title>Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.</article-title><source>Eur J Pharmacol</source><volume>396(2&#x02013;3)</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">10822068</pub-id></mixed-citation></ref><ref id="pone.0006409-Hasko1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasko</surname><given-names>G</given-names></name><name><surname>Cronstein</surname><given-names>BN</given-names></name></person-group><year>2004</year><article-title>Adenosine: An endogenous regulator of innate immunity.</article-title><source>Trends Immunol</source><volume>25(1)</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">14698282</pub-id></mixed-citation></ref><ref id="pone.0006409-Hasko2"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasko</surname><given-names>G</given-names></name><name><surname>Linden</surname><given-names>J</given-names></name><name><surname>Cronstein</surname><given-names>B</given-names></name><name><surname>Pacher</surname><given-names>P</given-names></name></person-group><year>2008</year><article-title>Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases.</article-title><source>Nat Rev Drug Discov</source><volume>7(9)</volume><fpage>759</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">18758473</pub-id></mixed-citation></ref><ref id="pone.0006409-Enoh1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoh</surname><given-names>VT</given-names></name><name><surname>Fairchild</surname><given-names>CD</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Varma</surname><given-names>TK</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name></person-group><year>2006</year><article-title>Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury.</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><volume>290(3)</volume><fpage>R685</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16269570</pub-id></mixed-citation></ref><ref id="pone.0006409-Enoh2"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoh</surname><given-names>VT</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Varma</surname><given-names>TK</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name></person-group><year>2006</year><article-title>Differential effect of imipenem treatment on injury caused by cecal ligation and puncture in wild-type and NK cell-deficient beta(2)-microgloblin knockout mice.</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>290(2)</volume><fpage>G277</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16166341</pub-id></mixed-citation></ref><ref id="pone.0006409-Leibovici1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibovici</surname><given-names>L</given-names></name><name><surname>Drucker</surname><given-names>M</given-names></name><name><surname>Konigsberger</surname><given-names>H</given-names></name><name><surname>Samra</surname><given-names>Z</given-names></name><name><surname>Harrari</surname><given-names>S</given-names></name><etal/></person-group><year>1997</year><article-title>Septic shock in bacteremic patients: Risk factors, features and prognosis.</article-title><source>Scand J Infect Dis</source><volume>29(1)</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9112302</pub-id></mixed-citation></ref><ref id="pone.0006409-Oberholzer2"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberholzer</surname><given-names>A</given-names></name><name><surname>Oberholzer</surname><given-names>C</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name></person-group><year>2002</year><article-title>Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug.</article-title><source>Crit Care Med</source><volume>30(1 Supp)</volume><fpage>S58</fpage><lpage>S63</lpage></mixed-citation></ref><ref id="pone.0006409-Zhu1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>LX</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Stolina</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>MD</given-names></name><etal/></person-group><year>2000</year><article-title>Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.</article-title><source>J Immunol</source><volume>165(1)</volume><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">10861074</pub-id></mixed-citation></ref><ref id="pone.0006409-Chung1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CS</given-names></name><name><surname>Xu</surname><given-names>YX</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name></person-group><year>1998</year><article-title>Is fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis?</article-title><source>Arch Surg</source><volume>133(11)</volume><fpage>1213</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">9820353</pub-id></mixed-citation></ref><ref id="pone.0006409-Hotchkiss4"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Tinsley</surname><given-names>KW</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Cobb</surname><given-names>JP</given-names></name><etal/></person-group><year>1999</year><article-title>Prevention of lymphocyte cell death in sepsis improves survival in mice.</article-title><source>Proc Natl Acad Sci U S A</source><volume>96(25)</volume><fpage>14541</fpage><lpage>14546</lpage><pub-id pub-id-type="pmid">10588741</pub-id></mixed-citation></ref><ref id="pone.0006409-Hotchkiss5"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Tinsley</surname><given-names>KW</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Schmieg</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Hui</surname><given-names>JJ</given-names></name><etal/></person-group><year>2001</year><article-title>Sepsis-induced apoptosis causes progressive profound depletion of B and CD4&#x0002b; T lymphocytes in humans.</article-title><source>J Immunol</source><volume>166(11)</volume><fpage>6952</fpage><lpage>6963</lpage><pub-id pub-id-type="pmid">11359857</pub-id></mixed-citation></ref><ref id="pone.0006409-Lombard1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombard</surname><given-names>C</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents.</article-title><source>Clin Immunol</source><volume>122(3)</volume><fpage>259</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">17185040</pub-id></mixed-citation></ref><ref id="pone.0006409-Rieder1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieder</surname><given-names>SA</given-names></name><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>P</given-names></name></person-group><year>2009</year><article-title>Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.</article-title><source>Immunobiology</source></mixed-citation></ref><ref id="pone.0006409-Jia1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Hegde</surname><given-names>VL</given-names></name><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>Sisco</surname><given-names>D</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Delta9-tetrahydrocannabinol-induced apoptosis in jurkat leukemia T cells is regulated by translocation of bad to mitochondria.</article-title><source>Mol Cancer Res</source><volume>4(8)</volume><fpage>549</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">16908594</pub-id></mixed-citation></ref><ref id="pone.0006409-McKallip1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKallip</surname><given-names>RJ</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Schlomer</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>JW</given-names></name><name><surname>Nagarkatti</surname><given-names>PS</given-names></name><etal/></person-group><year>2006</year><article-title>Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.</article-title><source>Mol Pharmacol</source><volume>70(3)</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">16754784</pub-id></mixed-citation></ref><ref id="pone.0006409-McKallip2"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKallip</surname><given-names>RJ</given-names></name><name><surname>Lombard</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>PS</given-names></name></person-group><year>2002</year><article-title>Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.</article-title><source>J Pharmacol Exp Ther</source><volume>302(2)</volume><fpage>451</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">12130702</pub-id></mixed-citation></ref><ref id="pone.0006409-Do1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>Y</given-names></name><name><surname>McKallip</surname><given-names>RJ</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>PS</given-names></name></person-group><year>2004</year><article-title>Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: Novel role for endogenous and exogenous cannabinoids in immunoregulation.</article-title><source>J Immunol</source><volume>173(4)</volume><fpage>2373</fpage><lpage>2382</lpage><pub-id pub-id-type="pmid">15294950</pub-id></mixed-citation></ref><ref id="pone.0006409-Maresz1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maresz</surname><given-names>K</given-names></name><name><surname>Pryce</surname><given-names>G</given-names></name><name><surname>Ponomarev</surname><given-names>ED</given-names></name><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Croxford</surname><given-names>JL</given-names></name><etal/></person-group><year>2007</year><article-title>Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.</article-title><source>Nat Med</source><volume>13(4)</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">17401376</pub-id></mixed-citation></ref><ref id="pone.0006409-Karsak1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsak</surname><given-names>M</given-names></name><name><surname>Gaffal</surname><given-names>E</given-names></name><name><surname>Date</surname><given-names>R</given-names></name><name><surname>Wang-Eckhardt</surname><given-names>L</given-names></name><name><surname>Rehnelt</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Attenuation of allergic contact dermatitis through the endocannabinoid system.</article-title><source>Science</source><volume>316(5830)</volume><fpage>1494</fpage><lpage>1497</lpage><pub-id pub-id-type="pmid">17556587</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by the National Institutes of Health (NIH) Grant GM066189-05A2 and the Intramural Research Program of NIH, National Institute on Alcohol Abuse and Alcoholism. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>